Brokers Set Expectations for Clovis Oncology’s FY2025 Earnings (NASDAQ:CLVS)


Share on StockTwits

Clovis Oncology (NASDAQ:CLVS) – Stock analysts at SVB Leerink issued their FY2025 earnings per share estimates for Clovis Oncology in a research note issued to investors on Tuesday, January 12th. SVB Leerink analyst A. Berens forecasts that the biopharmaceutical company will post earnings of ($0.14) per share for the year. SVB Leerink currently has a “Underperform” rating and a $3.00 price target on the stock.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.12. The business had revenue of $38.77 million for the quarter, compared to analyst estimates of $42.34 million.

CLVS has been the subject of several other reports. ValuEngine upgraded Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, November 10th. HC Wainwright reissued a “buy” rating on shares of Clovis Oncology in a report on Friday, January 8th. BidaskClub downgraded shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Monday, December 28th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Sunday, November 1st. Finally, Piper Sandler lowered their price objective on Clovis Oncology from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Thursday, November 5th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.92.

CLVS stock opened at $5.62 on Wednesday. The stock’s 50 day moving average is $4.97 and its two-hundred day moving average is $5.49. Clovis Oncology has a 52-week low of $3.62 and a 52-week high of $11.63. The company has a market capitalization of $496.35 million, a PE ratio of -1.07 and a beta of 2.10.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich boosted its position in Clovis Oncology by 33.3% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 10,000 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 2,500 shares during the period. Wedbush Securities Inc. boosted its holdings in shares of Clovis Oncology by 23.2% during the third quarter. Wedbush Securities Inc. now owns 15,950 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 3,000 shares during the period. Sheaff Brock Investment Advisors LLC grew its position in shares of Clovis Oncology by 25.9% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 14,591 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 3,000 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Clovis Oncology by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 47,315 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 3,917 shares during the period. Finally, Weld Capital Management LLC lifted its position in Clovis Oncology by 10.1% in the 3rd quarter. Weld Capital Management LLC now owns 43,886 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 4,020 shares during the last quarter. 57.83% of the stock is currently owned by institutional investors and hedge funds.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: Stop Order Uses For Individual Investors

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.